Supplementary Table 1. Dissociation cases of EI and Fibrosis Case 1 2

Slides:



Advertisements
Similar presentations
Infectious hepatitis Clinical manifestations: Asymptomatic Acute Chronic Asymptomatic carrier Hepatic failure Cirrhosis Hepatocellular carcinoma.
Advertisements

Jayaweera DT, Campa A, Casillas VJ, Martinez SS, Shin DH, Li Y, Young S, Baum MK.
V. Petrenkiene*, D. Petrauskas L. Kupcinskas, Lithuanian University of Health sciences Clinic of Gastroenterology Kaunas Utility of non-invasive markers.
Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.
Impact of weight management in chronic HCV Egyptian patients on liver fibrosis. By: Dr. Osama A. Fekry Lecturer of CN at the AUC Head of clinical Nutrition.
THE PRESENCE OF HEPATIC STEATOSIS WHEN NO OTHER CAUSES FOR SECONDARY HEPATIC FAT ACCUMULATION NAFLD MAY PROGRESS TO CIRRHOSIS AND IS LIKELY AN IMPORTANT.
Chronic Hepatitis B Diagnosis When to refer
Simple Noninvasive Systems Predict long-term Outcome of Patients With NAFLD Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera.
FT in prognostic of HBV FibroTest: predictive value in HBV.
Hepatocellular Carcinoma from the ACC to Med E Paul M. Johnson Department of Internal Medicine University of North Carolina Hospitals February 12, 2010.
Liver Stiffness Measurement Using Acoustic Radiation Force Impulse (ARFI) Elastography and Effect of Necroinflammation Ki Tae Yoon, Sun Min Lim,Jun Yong.
Quali differenze in rapporto al sesso nella monoinfezione HCV PITER cohort data Loreta Kondili Istituto Superiore di Sanità.
Date of download: 6/21/2016 From: HIV, Age, and the Severity of Hepatitis C Virus–Related Liver Disease: A Cohort Study Ann Intern Med. 2013;158(9):
Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C Robert J Fontana, Jules L Dienstag,
Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH.
Kris V. Kowdley, Patricia Belt, Laura A. Wilson, Matthew M. Yeh, Brent A. Neuschwander-Tetri, Naga Chalasani, Arun J. Sanyal, and James E. Nelson ; for.
Hepatic Steatosis in patients with Autoimmune Hepatitis (AIH) – prevalence, progression and possible significance C. Salmon*1, B.Hoeroldt2, A. Dube3,
Interpreting Your Test Results
Value in Health Regional Issues
Asymptomatic abnormal LFTs…..again!
Figure 1 Proposed risk stratification for patients with NAFLD
Aki Juhani Käräjämäki, Risto Bloigu, Heikki Kauma, Y
4th IAS Conference , Sydney, Australia, July 2007
Long-term impact of response to interferon-based therapy in patients with chronic HCV in relation to liver function, survival and cause of death Philip.
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer.
BCLC Outperforms HKLC Staging of Hepatocellular Carcinoma in Multiethnic Asians – Real-World Perspective ESPS Manuscript NO:
A New Model to Estimate Survival for Hepatocellular Carcinoma Patients
Metabolism - Clinical and Experimental
Clinical outcome after SVR: Veterans Affairs
Underwriting Screening Liver Test Abnormalities:
Volume 116, Issue 6, Pages (June 1999)
MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma Liver Cancer 2017;6: DOI: /
Journal Club Leona von Köckritz
HEPATOCELLULAR CARCINOMA (HCC) at
Volume 138, Issue 5, Pages e1 (May 2010)
Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.
Hepatocellular Carcinoma in Olmsted County, Minnesota,
Figure 1 Proposed algorithm for the management
Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis  Astrid Marot, Jean Henrion, Jean-François.
Hepatitis B and C virus-related carcinogenesis
Value in Health Regional Issues
Nat. Rev. Nephrol. doi: /nrneph
Supersonic Shear Imaging and Transient Elastography With the XL Probe Accurately Detect Fibrosis in Overweight or Obese Patients With Chronic Liver Disease 
Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection  Sahil Mittal, Jennifer R. Kramer, Ronald Omino,
AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary.
Clinical outcome after SVR: ANRS CO22 HEPATHER
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
Impact of metabolic risk factors on HCC
Volume 54, Issue 5, Pages (May 2011)
Volume 57, Issue 4, Pages (October 2012)
Autophagy in the liver Journal of Hepatology
Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States  Ju Dong Yang, Joseph.
Chan Wah Kheong, Nik Raihan Nik Mustapha, Sanjiv Mahadeva 
(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.
Hepatocellular Carcinoma in Patients with
High Prevalence of Hepatic Fibrosis, Measured by Elastography, in a Population-Based Study of Mexican Americans  Gordon P. Watt, Miryoung Lee, Jen-Jung.
Hepatitis B and C virus-related carcinogenesis
Volume 69, Issue 5, Pages (November 2018)
Volume 64, Issue 6, Pages (June 2016)
Ju Dong Yang, W. Ray Kim, Ritika Coelho, Teresa A. Mettler, Joanne T
Volume 140, Issue 1, Pages (January 2011)
Should we undertake surveillance for HCC in patients with NAFLD ??
Incidence of HCC after HCV treatment with DAAs: ERCHIVES
The metabolomic window into hepatobiliary disease
Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma  Jin-de Chen, Chun-jen Liu, Po-huang Lee, Pei-jer.
Markov model of HCV–HCC disease process.
Outcomes in liver transplantation: Does sex matter?
Public Health Policies and Alcohol-related Liver Disease
Fig. 4: Schematic, initial diagnostic algorithm for a patient presenting with mild aminotransferase abnormality. Fig. 4: Schematic, initial diagnostic.
Presentation transcript:

Supplementary Table 1. Dissociation cases of EI and Fibrosis Case 1 2 3 4 5 6 7 8 9 10 Age 59 26 69 54 88 64 67 Sex M F BMI 20.4 31.2 28.4 27.2 21.2 18.4 21.8 24.2 20.3 27.5 Etiology HBV NAFLD HCV AIH HyA 53.3 22.8 51.5 20.9 52.9 1320 226 166 223 67.0 4C7 3.5 5.2 4.2 4.5 9.1 11.0 6.7 6.3 8.7 APRI 0.5 1.8 0.6 0.9 3.4 3.1 0.7 2.3 FIB-4 1.7 0.8 2.3 1.9 4.3 10.9 5.6 3.5 2.4 8.9 EI 3.0 3.8 4.2 4.5 2.6 2.4 Fibrosis F0 F1 F2 F3 F4 Method* Op Bp M, male; F, female; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; AIH, autoimmune hepatitis; NAFLD, non-alcoholic fatty liver disease; HyA, hyaluronic acid; 4C7, type 4 collagen 7S; APRI, aspartate aminotransferase to platelet ratio index; EI, elasticity index; HCC, hepatocellular carcinoma, Op, operation; Bp, liver biopsy. Asterisk means the method to obtain liver histology. Operation had been performed for the treatment of HCC.

Supplementary Table 2. Intraclass correlation coefficient (ICC) in strain elastography Cohort Whole cohort HCV HBV AL/NAFLD n 193 88 41 35 Mean BMI 24.3 24.2 23.8 25.3* ICC 0.835 0.859 0.792 0.703 95% confidential index 0.780-0.875 0.609-0.889 0.785-0.908 0.412-0.850 * Asterisk means statistically significant differences between AL/NAFLD group and other groups. BMI, body mass index; HCV, hepatitis C virus; HBV, hepatitis B virus; AL, alcohol; NAFL, non-alcoholic fatty liver.

Supplementary Fig. 1 BCLC-O, A BCLC-B Cumulative survival rate BCLC-C Survival time (months) Cumulative survival rate BCLC-O, A BCLC-B BCLC-C BCLC-D P<0.001 in log-rank test